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Abstract
Tuberculosis is a global health problem and at least one-third of the world’s population is
infected with Mycobacterium tuberculosis (MTB). MTB is a successful pathogen that en-
hances its own intracellular survival by inhibiting inflammation and arresting phago-lysosomal
fusion. We previously demonstrated that Toxoplasma gondii (T. gondii) dense granule anti-
gen (GRA) 7 interacts with TNF receptor-associated factor 6 via Myeloid differentiation pri-
mary response gene 88, enabling innate immune responses in macrophages. To extend
these studies, we found that GRA7 interacts with host proteins involved in antimicrobial host
defense mechanisms as a therapeutic strategy for tuberculosis. Here, we show that protein
kinase C (PKC)α-mediated phosphorylation of T. gondii GRA7-I (Ser52) regulates the inter-
action of GRA7 with PYD domain of apoptosis-associated speck-like protein containing a car-
boxy-terminal CARD, which is capable of oligomerization and inflammasome activation can
lead to antimicrobial defense against MTB. Furthermore, GRA7-III interacted with the PX
domain of phospholipase D1, facilitating its enzyme activity, phago-lysosomal maturation,
and subsequent antimicrobial activity in a GRA7-III (Ser135) phosphorylation-dependent
manner via PKCα. Taken together, these results underscore a previously unrecognized
role of GRA7 in modulating antimicrobial host defense mechanism during mycobacterial
infection.
Author Summary
We previously demonstrated that Toxoplasma gondii (T. gondii) dense granule antigen
(GRA) 7 interacts with TRAF6 via MyD88, enabling innate immune responses in macro-
phages and effective protection against T. gondii infection in vivo. However, its exact role
and how it regulates host innate immune responses have not been fully explained. Herein,
we show that PKCα-mediated phosphorylation of GRA7 is essential for the interaction
between GRA7 and ASC or PLD1, which can promote antimicrobial defense against
Mycobacterium tuberculosis (MTB). Notably, PKCα specifically phosphorylated Ser52
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and Ser135 of GRA7 in vitro and in vivo, indicating that GRA7 is a substrate of PKCα.
The N-terminal of GRA7 (GRA7-I) was sufficient for interaction with the PYD domain
of ASC, which is capable of ASC oligomerization and inflammasome activation. Further-
more, GRA7-III interacted with the PX domain of PLD1, facilitating its enzyme activity,
phago-lysosomal maturation, and subsequent antimicrobial activity in a GRA7 phosphor-
ylation-dependent manner. Interestingly, phosphomimetic mutation in GRA7 overcame
the need for PKCα. Collectively, these results provide novel insight into how GRA7 can
promote ASC and PLD1 activation in a PKCα-dependent manner as an antimicrobial
host defense mechanism.
Introduction
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) [1].
The World Health Organization reported that in 2014, 9.6 million cases and 1.5 million deaths
were globally [2]. Recent developments in TB drug-development strategies (including new and
repurposed antimicrobials and host-directed drugs) have produced new regimens to shorten
treatment duration, improve outcomes of TB treatment such as, prevent resistance, reduce
lung injury by promoting autophagy, antimicrobial peptide production, and other macro-
phage effector mechanisms, as well as inhibiting mechanisms causing lung inflammation and
matrix destruction [1,3–5]. A wide range of candidate host-directed therapies (HDTs)-includ-
ing new and repurposed drugs, biologics, and cellular therapies-have been proposed to acceler-
ate eradication of infection and overcome the problems associated with current treatment
regimens.
Recent studies have revealed the intracellular signaling pathways that govern the outcome
of the innate immune response to mycobacteria infection and antibacterial defense [6–11].
First, the NLRP3 inflammasome complex, an intracellular protein complex consisting of the
sensor NACHT, LRR and PYD domains-containing protein 3 (NLRP3), the adaptor apopto-
sis-associated speck-like protein containing a carboxy-terminal CARD (ASC), and pro-cas-
pase-1 regulates IL-1β and IL-18 processing [10–12]. Jayaraman et al. showed that IL-1β
directly promotes antimicrobial immunity in murine and human macrophages by regulating
TNFR signaling and caspase-3 activation against MTB infection [10]. Verway et al. showed
that 1-25-Dihydroxyvitamin D (1,25D) enhances IL-1β signaling from MTB-infected macro-
phages, inducing antimicrobial peptide DEFB4/HBD2 in primary lung epithelial cells, which
in turn helps control MTB [11]. Second, host phospholipids play a critical role in the activation
of the antimicrobial innate immune response [13]. Phospholipase D (PLD), which has two iso-
forms (PLD1 and PLD2) catalyzes the hydrolysis of the membrane phospholipid, phosphati-
dylcholine, to generate the metabolically active phosphatidic acid (PA) [14]. PLD1 is activated
by arf-, ral-, and rho-family GTPases, and protein kinase C (PKC) α, while PLD2 activity is ele-
vated by fatty acids [15]. Interestingly, MTB, unlike the nonpathogenic M. smegmatis, inhibits
PLD activation during phagocytosis, a process that is associated with intracellular survival of
the pathogen [6]. Garg et al. showed that Natural lysophospholipids promote MTB-induced in
vitro PLD-dependent phagolysosome maturation and PLD-dependent intracellular killing of
MTB in human macrophages [8] and the type II alveolar epithelial cell line A549 [9]. Third,
recent studies have highlighted the role of protein kinases in the biology and pathogenesis of
mycobacteria. The members of the PKC-family of proteins are classified into three groups,
based on the mechanisms regulating their activation in response to different stimuli [7,16].
Holm et al. showed that PKCα regulates phagocytosis and the biogenesis of phagolysosomes
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by promoting the interaction of phagosomes with late endosomes and lysosomes [16]. Fur-
thermore, PKCα also plays an important role in the killing of MTB in human macrophages
[7]. Collectively, these infection-induced signaling pathways suggest possibilities for the devel-
opment of novel therapeutic modalities for tuberculosis that target the intracellular signaling
pathways permitting the replication of this nefarious pathogen. However, the roles of MTB-
infection signal-dependent HDTs involved in host innate immune responses and their regula-
tory mechanisms have not yet been fully elucidated.
In a previous study, we demonstrated that T. gondii GRA7/MyD88-dependent NF-κB acti-
vation is essential for the activation of TNF receptor-associated factor 6 (TRAF6) and ROS
generation, and enhances the release of inflammatory mediators. We also found that GRA7
stimulation led to physical and functional associations between GRA7 and TRAF6, resulting
in crucial protective efficacy against T. gondii infection in vivo [17]. It remains to be seen
whether GRA7 targeting can be used as a therapeutic strategy for infectious diseases. In this
study, we further investigated the intracellular regulatory network of T. gondii GRA7-induced
ASC, PLD1, and PKCα signaling pathways to help identify novel therapeutic modalities for
tuberculosis. We found that the PKCα-mediated phosphorylation of GRA7 was essential for
interaction between GRA7 and ASC or PLD1, which contributes to antimicrobial defense
against MTB in vitro and in vivo. Our findings demonstrate that GRA7-I and -III play fine-
tuning roles in the activation of HDTs and innate immune machineries through direct binding
with ASC or PLD1 and may provide a unique opportunity for urgently needed therapeutic
interventions against tuberculosis.
Materials and Methods
Ethic statement
All animal experimental procedures were reviewed and approved by the Institutional Animal
Care and Use Committee of Hanyang University (protocol 2014–0207) and Bioleaders Corpo-
ration (Daejeon, Korea, protocol BLS-ABSL3-13-11). All animal experiments were performed
in accordance with Korean Food and Drug Administration (KFDA) guidelines.
M. tuberculosis culture
Cultures of MTB H37Rv (provided by Dr. R. L. Friedman, University of Arizona, Tucson, AZ)
were prepared as described previously [1]. The effective concentration of lipopolysaccharide
was<50 pg/ml in those experiments, with a bacterium-to-cell ratio of 10:1. For all assays, mid-
log phase bacteria (absorbance 0.4) were used. Bacterial strains were divided into 1-ml aliquots
and stored at -70˚C.
Mice and cells
Wild-type C57BL/6 mice were purchased from Orient Bio (Gyeonggi-do, Korea). PKCα-/- (B6;
129-Prkcatm1Jmk/J, 009068) and PLD1-/- (B6.Cg-Pld1tm1.1Gbp/J, 028665) mice were obtained from
Jackson Laboratory. All animals were maintained in a specific pathogen-free environment. HEK
293T cells (ATCC-11268; American Type Culture Collection) were maintained in DMEM (Invi-
trogen) containing 10% FBS (Invitrogen), sodium pyruvate, nonessential amino acids, penicillin
G (100 IU/ml), and streptomycin (100 μg/ml). Human monocytic THP-1 (ATCC TIB-202) cells
were grown in RPMI 1640/glutamax supplemented with 10% FBS and treated with 20nM PMA
(Sigma-Aldrich) for 24 h to induce their differentiation into macrophage-like cells, followed by
washing three times with PBS. Primary bone marrow–derived macrophages (BMDMs) were
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isolated from C57BL/6 mice and cultured in DMEM for 3–5 d in the presence of M-CSF (R&D
Systems, 416-ML), as described previously [12].
M. tuberculosis infection in vitro and in vivo
For in vitro experiments, cells were infected with MTB for 2–4 h. Then, cells were washed with
PBS to remove extracellular bacteria, supplied with fresh medium, and incubated at 37˚C for
indicated time points. For in vivo experiments, C57BL/6 mice were i.v. injected with MTB
(1×106 CFU/mouse). After 3 wks of infection, mice injected intraperitoneally with rGRA7 pro-
teins for 7 consecutive days. After 1 wk of treatment, mice were sacrificed for harvesting of the
lungs, spleens, and livers. Mice were maintained in biosafety level 3 laboratory facilities.
Reagents, plasmids, and abs
CIP (P4978) and DMSO were purchased from Sigma-Aldrich. PKCα (C2-4) inhibitor peptide
(17478) was purchased from Cayman Chemical. Flag-PKCα, -β, -δ, and -ξ plasmids were a
generous gift from Dr. D. Zhou (Xiamen University, China). The GST-tagged GRA7 and trun-
cated mutant genes were described previously [17]. V5-tagged AC or AU1-PLD1 and trun-
cated mutant genes were cloned into the XbaI and BamHI sites in pcDNA3.0. All constructs
were sequenced using an ABI PRISM 377 automatic DNA sequencer to verify 100% corre-
spondence with the original sequence. Specific antibodies against phospho-(Thr147)-PLD1
(3831), phospho-(Ser561)-PLD2 (3834), PLD1 (3832), PLD2 (13904), PKCα (2056), PKCγ
(43806), and NLRP4 (12421) were purchased from Cell Signaling Technology. Antibodies spe-
cific for actin (I-19), ASC (N-15-R), IL-18 (H-173-Y), TRAF6 (H-274), caspase-1 p10 (M-20),
Rab5 (D-11), Rab7 (H-50), LAMP1 (E-5), LAMP2 (H4B4), Tubulin (B-5-1-2), Calnexin (H-
70), FACL4 (N-18), VDAC (B-6), His (His17), V5 (C-9), Flag (D-8), and GST (B-14) were pur-
chased from Santa Cruz Biotechnology. AU1 (GTX23402) and PKCβI (A10-F) were purchased
from GenenTex and Antibodies-online Inc., respectively. IL-1β (AF-401-NA) and NLRP3
(AG-20B-0014) were from R&D Systems and Adipogen, respectively.
Immunoblot analysis and immunoprecipitation
THP-1, 293T, and BMDMs were treated as indicated and processed for analysis by Western
blotting, co-immunoprecipitation, and GST pulldown as previously described [17,18].
Confocal fluorescence microscopy
Immunofluorescence analysis was performed as described previously [1]. The cells were fixed
on coverslips with 4% (w/v) paraformaldehyde in PBS and then permeabilized for 10 min
using 0.25% (v/v) Triton X-100 in PBS at 25˚C. PLD1 or His was detected using a 1/100 dilu-
tion of the primary Ab for 1 h at 25˚C. After washing, the appropriate fluorescently labeled
secondary Abs were incubated for 1 h at 25˚C. Slides were examined using laser-scanning con-
focal microscopy (model LSM 800; Zeiss). For colocalization analysis, the co-distribution of
the PLD1 and GRA7 were quantified and validated statistically by Pearson coefficient, as speci-
fied by the ZEN 2009 software (version 5.5 SP1; Zeiss).
Peptide spot arrays
Peptide arrays were synthesized using the SPOTs synthesis method and spotted onto a deriva-
tized cellulose membrane (Intavis) in the presence of [γ-32P]ATP and calcium as described
previously [19,20]. Peptide spot phosphorylation was quantified using phosphoimaging.
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Histology
For immunohistochemistry of tissue sections, mouse lungs were fixed in 10% formalin and
embedded in paraffin. Paraffin sections (4 μm) were cut and stained with hematoxylin and
eosin (H&E) [21].
In vitro PLD activity assay
PLD activity was measured using the Amplex Red PLD assay kit (Molecular Probes, A12219)
according to the manufacturer’s protocol. The resulting fluorescence was detected using a fluo-
rescence microplate reader at an excitation of 530 nm and an emission of 590 nm.
Recombinant GRA7 protein
The recombinant GRA7 protein was described previously [17]. GRA7s from amino acid resi-
dues 26–80, 26-80S52A, 26-80S52D, 120-150S135A and 120-150S135D were cloned with an N-ter-
minal 6xHis-tag into the pRSFDuet-1 Vector (Novagen) and induced, harvested, and purified
from E. coli expression strain BL-21 DE-3 pLysS, as described previously [17,22], following
standard protocols recommended by Novagen.
Supplemental Information
Supplemental experimental procedures and supplemental references.
Statistical analysis
All data were analyzed by Student’s t-test with Bonferroni adjustment or ANOVA for multiple
comparisons, and are presented as mean ± SD. Grubbs’ test was used for evaluating the outli-
ers. Differences were considered significant at p<0.05.
Results
GRA7 associates with ASC and PLD1
To establish a role for GRA7 in intracellular signaling pathways as a therapeutic strategy for
infectious diseases in macrophages, we investigated whether GRA7 interacts with molecules
involved in innate immunity. GRA7 complexes were subjected to co-immunoprecipitation
(co-IP) of recombinant GRA7 protein with THP-1 lysates. The purified GRA7 complexes
retrieved several endogenous proteins selectively, as identified by mass spectrometry analysis,
including PLD1 (124 K), PKCα (76 K), ASC (21 K), and TRAF6 (60 K) (Fig 1A and S1 Fig).
Endogenous co-IP showed that GRA7 interacted strongly, although temporarily (from 15 to
60 min), with endogenous PLD1, TRAF6, and ASC but not with PLD2, NLRP3, or NLRC4
after stimulation with rGRA7 in THP-1 cells, and vice versa (Fig 1B, S2A and S2B Fig). As
previously reported [17], GRA7 associated with TRAF6, based on their molecular weights
and co-IP (Fig 1A–1C, S1 and S2A Figs).
To determine the mechanism by which rGRA7 interact with the intracellular protein, THP-1
cells were preincubated with cytochalasin D, which inhibits actin polymerization. Pretreatment
with cytochalasin D completely blocked the phagocytic activities of rGRA7 and it binding with
intracellular proteins (S2C and S2D Fig).
Structurally, GRA7 contains a signal sequence, N-terminal domains (I–IV), a trans-
membrane, and a C-terminal domain (V) (Fig 1C) [17]. In 293T cells, detailed mapping
using various mammalian glutathionine S-transferase (GST)-GRA7 fusions and truncated
mutants of V5-ASC indicated that the N-terminal I-domain (aa26-80) of GRA7 exhibited
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only minimal binding affinity to ASC and ASC carrying the N-terminal PYD domain
(aa1-91) bound GRA7 as strongly as ASC WT (Fig 1C and 1D). GST pull-down assays
using truncated mutants of GST-GRA7 mammalian fusions and AU1-PLD1 showed that
the N-terminal III-domain (aa120-150) of GRA7 is required for its interaction with PX
(aa81-212) of PLD1 (Fig 1C and 1E and S2E Fig), indicating that the interactions of GRA7
with ASC, PLD1, and TRAF6 are genetically separable (Fig 1). These results show that
GRA7 interacts with ASC and PLD1 through its N-terminal I- and III-domains in macro-
phages, respectively.
Fig 1. GRA7 interactions with ASC and PLD1. (A) Identification of PLD1, PKCα, TRAF6, and ASC by mass spectrometry analysis in THP-1 cell
lysates incubated with a His-tagged rGRA7 (2 μg). CoBlue, staining of His-rGRA7 with Coomassie blue. Whole cell lysates (WCLs) were used for
immuno blotting (IB) with αActin. (B) THP-1 cells were stimulated with rGRA7 (5 μg/ml) for the indicated times, followed by immunoprecipitation (IP)
with αHis-agarose bead and IB with αPLD1, αTRAF6, αASC, αHis, and αActin. (C) Summary of the interactions of GRA7 WT and its mutants with ASC,
PLD1, and TRAF6. The binding activities of GRA7 WT and mutants are summarized based on the results of Fig 1D and 1E, S2E Fig, and [17]. (D and
E) Binding mapping. Schematic diagram of the structures of ASC and PLD1 (upper). (D) At 48 hr post-transfection with mammalian GST or GST-GRA7
and truncated mutant constructs together with V5-ASC (left), V5, or V5-ASC constructs together with GST-GRA7 (right), 293T cells were used for GST
pulldown, followed by IB with αV5. WCLs were used for IB with αGST, αV5 or αActin. (E) 293T cells were co-transfected with GST or GST-GRA7 and
truncated mutant constructs together with AU1-PLD1 (left), or AU1 or AU1-PLD1 constructs together with GST-GRA7 (right), and subjected to GST
pulldown, followed by IB with αAU1. WCLs were used for IB with αGST, αAU1 or αActin. The data are representative of four independent experiments
with similar results (A, B, D, E).
doi:10.1371/journal.ppat.1006126.g001
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GRA7 interaction with ASC and PLD1 via PKCα
In addition to ASC and PLD1 binding, GRA7 also interacted with PKCα. Endogenous co-IP
revealed a robust interaction between GRA7 and PKCα, but not PKCβI or PKCγ, after stimu-
lation with rGRA7 in THP-1 cells, and vice versa (Fig 2A).
A large-scale proteomics analysis of the human kinome [23] and computational sequence
analysis [24] predicted five PKC phosphorylation residues (S52LR, T121DR, S135FK, T204TR,
S209PR) within the GRA7 N-terminal I, III domains, and C-terminal V-domain. To confirm
that GRA7 was phosphorylated by PKCα, we used several strategies. First, we performed Phos-
tag gel electrophoresis, which involves the use of a Phos-tag biomolecule that specifically binds
Fig 2. PKCα-dependent phosphorylation of GRA7 was essential for interaction with ASC and PLD1. (A) THP-1 cells were stimulated with
rGRA7 (5 μg/ml) for the indicated times (left) or 30 min. (right), followed by IP with αHis-agarose bead (left) or αPKCα (right) and IB with αPKCα,
αPKCβI, αPKCγ, αHis, and αActin. (B) Phos-tag and SDS-PAGE analyses of GST-GRA7, GRA7-IWT, GRA7-IS52A, GRA7-IIIWT, GRA7-IIIT121A, or
GRA7-IIIS135A expressed together with Flag-tagged PKCα in 293T cells left untreated (CIP-) or treated with calf intestinal alkaline phosphatase (CIP+),
and subjected to GST pulldown, followed by IB with αGST. WCLs were used for IB with αFlag or αActin. (C) Mapping of PKCα phosphorylation sites on
GRA7 by tiled peptide array analysis using purified recombinant PKCα. Phosphorylation intensity of 15-amino acid peptides that span full-length GRA7
and are each shifted by 3 amino acids was detected using MultiGauge version 3.0. The serines in the two peptides that showed a phosphorylation
signal stronger than 100 PSL/mm2 are indicated above the corresponding peaks. (D) 293T cells were co-transfected with GST or GST-GRA7-I and
truncated mutant constructs together with V5-ASC (left), or GST or GST-GRA7-III and truncated mutant constructs together with AU1-PLD1 (right), and
subjected to GST pulldown, followed by IB with αV5 or αAU1. WCLs were used for IB with αGST, αV5, αAU1, αPKCα, or αActin. (E) BMDMs from
PKCα+/+ and PKCα-/- were stimulated with rGRA7 for 30 min., followed by IP with αHis-agarose bead and IB with αASC, αPLD1, αPKCα, and αActin.
The data are representative of four independent experiments with similar results (A to E).
doi:10.1371/journal.ppat.1006126.g002
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phosphorylated proteins and retards their migration in the gel [25]. The results showed that
GRA7 of wild-type, I-, and III-domains migrated more slowly and produced an ‘up-shifted’
band (as visualized by the Phos-tag labeling system for the analysis of phosphorylation, fol-
lowed by SDS-PAGE) when co-expressed with PKCα, but when co-expressed with PKCβ,
PKCδ, or PKCξ (Fig 2B and S3A Fig). Furthermore, we performed an in vitro phosphorylation
assay using purified recombinant PKCα and a non-biased overlapping peptide array covering
the entire GRA7 sequence [19,20]. From GRA7, two peptides (49PVDSLRPTNAGVDSK73 and
121TDRKVVPRKSEGKRS135) showed a phosphorylation signal >200 PSL/mm2 (Fig 2C). In
contrast, none of the peptides spanning the C-terminal of GRA7 showed a significant phos-
phorylation signal. GRA7 has serine/threonine residues, and two peptides of GRA7 that were
phosphorylated contained three potential phosphorylation sites (Fig 2C and 2D). Interestingly,
the specific point mutation forms (IS52A and IIIS135A) of GRA7 markedly decreased phosphor-
ylation in Phos-tag gel electrophoresis, whereas the mutant IIIT121A of GRA7 did not (Fig 2B).
These results indicate that PKCα can specifically phosphorylate S52 and S135 residues of
GRA7, demonstrating that GRA7 is a substrate of PKCα.
We next investigated whether phosphorylation of S52 and S135 of GRA7 was necessary for
binding with ASC and PLD1, respectively. The point mutation (IS52A and IIIS135A) of GRA7
markedly abolished its interaction with ASC and PLD1, suggesting that this interaction is S52-
and S135-phosphorylation dependent (Fig 2D and S3B Fig). Furthermore, because phospho-
mimetic residues (aspartic acid or glutamic acid) do not fully approximate the electronegativ-
ity produced by phosphorylation, we employed the strategy of mutating amino acids to
overcome the charge differential [20,26]. The GST pull-down assay showed that phosphomi-
metic mutants of GRA7 strongly bound to ASC and PLD1 compared to GRA7 WT, indicating
that mimicking constitutively phosphorylated GRA7 overrode the need for PKCα function in
the innate immune pathway. Consistent with the findings shown in Fig 2A–2D, GRA7 interac-
tion with ASC and PLD1 was markedly decreased in BMDMs from PKCα-/- mice, THP-1
from knock down with shRNA specific for PKCα (Fig 2E and S3C Fig), and BMDMs treated
with a pharmacological inhibitor of PKCα upon rGRA7 stimulation (S3D Fig). Taken
together, these data indicate that PKCα-mediated phosphorylation of GRA7 at Ser52 or
Ser135 is essential for interactions between GRA7 and ASC or PLD1, respectively.
GRA7-I induces activation of ASC-dependent inflammasome
To examine the role of T. gondii GRA7-I in innate immune responses of macrophages, we
generated bacterially purified His-tagged GRA7-I and its mutant proteins, as described previ-
ously [17,22]. The purified rGRA7-I (10 kDa) was confirmed through SDS-PAGE and immu-
noblotting analysis (Fig 3A). No significant difference compared to vector control observed
for rGRA7-induced cytotoxicity in macrophages [17].
We showed previously that rGRA7-induced expression of pro-inflammatory cytokine
genes and proteins including IL-1β, in macrophages [17] and NLRP3 inflammasomes involves
a multimeric protein complex containing NLRP3 interacting the adaptor ASC and caspase-1
to induce the maturation of IL-1β and IL-18 [10,12]. To investigate the role of GRA7-I in the
regulation of inflammasome activation, BMDMs from PKCα+/+ and PKCα-/- mice were stimu-
lated with rGRA7-I and its mutant proteins. In response to rGRA7-I and -WT, PKCα-deficient
BMDMs showed significantly attenuated IL-1β and IL-18 production than WT BMDMs, but
the phosphomimetic mutant (IS52D)-induced markedly increased secretion of IL-1β and IL-18
(Fig 3B and S4A Fig). Consistent with these results, the caspase-1 activation and IL-1β and
IL-18 maturation observed in response to rGRA7-I and -WT proteins were significantly
decreased in PKCα-deficient BMDMs, and the constitutively active form (IS52D) of GRA7
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‘rescued’ the PKCα deficiency (Fig 3C). Notably, the PKCα non-phosphorylatable mutant
(IS52A) and shRNA-mediated reduction of endogenous ASC expression led to significant atten-
uation of IL-1β and IL-18 production (Fig 3B and S4B Fig) in an ASC-binding dependent
manner.
Next, we determined whether ASC is substantially oligomerized and if the intracellular forma-
tion of ASC specks is dependent on GRA7-I interaction. In correlation with secretion of active cas-
pase-1 and IL-1β, PKCα-deficient BMDMs showed markedly attenuated ASC oligomerization and
speck formation compared to WT BMDMs, but the phosphomimetic mutant (IS52D) markedly
Fig 3. GRA7-I activated inflammasomes in an ASC-binding dependent manner. (A) Bacterially purified 6xHis-GRA7-I and its mutants were analyzed by
Coomassie blue staining (left) or IB with αHis (right). (B) BMDMs from PKCα+/+ and PKCα-/- (left) or BMDMs were transduced with lentivirus-shRNA-NS or
lentivirus-shRNA-ASC (MOI = 100) with polybrene (8 μg/mL) (right) for 2 days, the cells were stimulated with rGRA7 (5 μg/ml) and its mutants for the indicated
times and culture supernatants were harvested and analyzed for cytokine ELISA for IL-1β and IL-18. Data shown are the means ± SD of five experiments.
Significant differences (*P < 0.05; ***P < 0.001) compared with PKCα+/+ or shRNA-NS. (C) IB analysis for IL-1β p17, IL-18 p18, or caspase-1 p10 in
supernatants (SN), ASC, NLRP3, pro-IL-1β, pro-IL-18, or pro-caspase-1 in whole-cell lysates (WCL). Actin was used as a loading control. (D) IB analysis of
lysates of BMDMs as in B and C solubilized with Triton X-100–containing buffer, followed by cross-linkage of insoluble fractions with disuccinimidyl suberate to
capture ASC oligomers and analysis of those fractions (I + DSS) and soluble fractions (S) with antibody to ASC. Actin was used as a loading control. (E)
Fluorescence confocal images showing formation of speck-like ASC pyroptosomes in BMDMs from PKCα+/+ and PKCα-/- mice were stimulated with rGRA7
and its mutants for 18 h, fixed, immunostained with antibodies for ASC (Alexa 488). Scale bar, 10 μm. The data are representative of five independent
experiments with similar results (A and C-E).
doi:10.1371/journal.ppat.1006126.g003
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increased both (Fig 3D and 3E and S4C Fig). Further, the intracellular interaction of GRA7 and
ASC was confirmed by their co-localization after stimulation with rGRA7. Subcellular fraction-
ation and co-IP analysis showed that GRA7-I associated with ASC and PKCα in the mitochondrial
fraction in PKCα+/+ BMDMs. Notably, these binding patterns were increased by the phosphomi-
metic mutant (IS52D) in BMDMs from PKCα+/+ and PKCα-/- mice (S4D Fig). These data suggest
that GRA7-I acts as a positive regulator of ASC-dependent inflammasome activation via PKCα in
mitochondria.
GRA7-I-induced activation of ASC-dependent inflammasomes is
important for resistance against MTB infection
IL-1β and IL-18 are cytokines that play crucial roles in host defense and inflammation [11,12].
We first measured caspase-1 activation and maturation of IL-1β and IL-18 induced by rGRA7
and its mutants in MTB-infected macrophages. rGRA7-I treatment increased inflammasome
activity in MTB-infected macrophages in a dose, ASC-binding and PKCα phosphorylation-
dependent manner. Importantly, treatment with the phosphomimetic mutant (IS52D) of GRA7
markedly amplified inflammasome activity in MTB-infected conditions in BMDMs from
PKCα+/+ and PKCα-/- mice (Fig 4A). The PKCα non-phosphorylatable mutant (IS52A) and the
shRNA-mediated reduction of endogenous ASC expression led to significant attenuation of
caspase-1 activation and maturation of IL-1β and IL-18 (Fig 4A and 4B) in an ASC-binding
dependent manner.
IL-1β directly activates MTB–infected macrophages to restrict intracellular bacterial repli-
cation [10,27]. We examined whether rGRA7-induced antimicrobial activity was dependent
on ASC-dependent inflammasome activation via PKCα in macrophages. The rGRA7-WT and
-I-induced antimicrobial responses against MTB were significantly downregulated in BMDMs
from PKCα-/- mice and cells transduced with shASC in a dose-dependent manner (Fig 4C and
4D). Notably, the PKCα non-phosphorylatable mutant (IS52A) of GRA7 did not induced anti-
microbial responses of MTB, compared with the WT- and rGRA7-I treatment, in BMDMs
from PKCα+/+ mice. The phosphomimetic mutant (IS52D) of GRA7 markedly increased anti-
microbial responses to MTB in dose-dependent manner, indicating that the constitutively
active form (IS52D) of GRA7 partially ‘rescued’ the PKCα deficiency. No significant difference
was observed for MTB growth in 7H9 broth with or without rGRA7 (S5 Fig), indicating that
ASC-dependent inflammasome-derived IL-1β controls the outcome of MTB infection and is
functionally linked via PKCα in macrophages.
GRA7-III induces activation of PLD1
To examine the role of T. gondii GRA7-III in innate immune responses by macrophages, we
generated bacterially purified His-tagged GRA7-III and its mutant proteins, as described pre-
viously [17,22]. The purified rGRA7-III (5 kDa) was confirmed through SDS-PAGE and
immunoblotting analysis (Fig 5A).
As GRA7 associates with PLD1 but not PLD2 (Fig 1 and S1 Fig), we sought to determine
whether PLD1 activation by GRA7-III was regulated by phosphorylation events in many cellu-
lar processes [15,28]. PLD1 activity is regulated by phosphorylation of Thr147 in the PX domain
and Ser561 in the negative regulatory loop region of PLD1 by PKCα [15,28]. We first measured
rGRA7-III-induced phosphorylation of PLD1 at Thr147 and Ser561 but not the PKCα non-
phosphorylatable mutant (IIIS135A) of GRA7 in macrophages. Importantly, the phosphomimetic
mutant (IIIS135D) of GRA7 treatment markedly amplified PLD1 activation in BMDMs from
PKCα+/+ and PKCα-/- mice (Fig 5B). Consistent with these results, PLD activity was signifi-
cantly decreased by the PKCα non-phosphorylatable mutant (IIIS135A) and increased by the
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phosphomimetic mutant (IIIS135D) of GRA7 in BMDMs from PKCα+/+ and PKCα-/- mice (Fig
5C). However, PLD activity was at the basal level in PLD1-/- macrophages with the phosphomi-
metic mutant, indicating that phosphorylated GRA7-III interacted with activated PLD1 by
PKCα and stimulated its enzymatic activity through the phosphorylation of PLD1 Thr147 and
Ser561. Further, the intracellular interaction of GRA7 and PLD1 was confirmed by their co-
localization after stimulation with rGRA7, as documented by immunostaining and image over-
lay (Fig 5D and S6 Fig). GRA7-III localized with PLD1 and PKCα in the cytoplasm, appearing
as small speckles and punctate spots. Notably, these co-localization patterns were increased by
the phosphomimetic mutant (IS135D) in BMDMs from PKCα+/+ and PKCα-/- mice, but not
Fig 4. GRA7-I-induced inflammasome activation was required for antimicrobial activity in MTB-infected macrophages. (A and B)
BMDMs from PKCα+/+ and PKCα-/- mice (A) and BMDMs were transduced with lentivirus-shRNA-NS or lentivirus-shRNA-ASC for 2 days (B)
infected with MTB (MOI = 1) for 4 h and then stimulated with rGRA7 (1, 5, 10 μg/ml) and its mutants for 18 h. IB analysis for IL-1β p17, IL-18
p18, or caspase-1 p10 in supernatants (SN), ASC, NLRP3, pro-IL-1β, pro-IL-18, or pro-caspase-1 in whole-cell lysates (WCL). Actin was used
as a loading control. (C and D) Intracellular survival of MTB was assessed by CFU assay. BMDMs were infected with MTB for 4 h, followed by
treatment with rGRA7, and then lysed to determine intracellular bacterial loads. The data are representative of five independent experiments
with similar results (A and B). Data shown are the mean ± SD of five experiments (C and D). Significant differences (*P < 0.05; **P < 0.01;
***P < 0.001) compared with rVector. CFU, colony-forming units. ns, not significant.
doi:10.1371/journal.ppat.1006126.g004
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PLD1-/- mice. These data suggest that GRA7-III acts as a positive regulator of PLD1 activation
via PKCα in macrophages.
GRA7-III-induced phagosome maturation of PLD1 is important for
resistance against MTB infection
PLD1 activity regulates the actin cytoskeleton, vesicle trafficking for secretion and endocytosis,
and receptor signaling. With the emerging concept of dynamic cycling of PLD1 inside the
cell, some of the varying reports of localization may be due to differential rates and numbers
of vesicles cycling in the cell lines used and thus differential regulation of PLD1 localization
[14,15,28]. MTB preferentially infects alveolar macrophages, although mycobacteria allow only
early endosome membrane fusion and induce phagosome arrest by selective Rab GTPase
recruitment to avoid fusion with late endosomes and lysosomes [29,30]. To investigate the sub-
cellular fractionation of PLD1, we treated MTB-infected BMDMs with rGRA7 and its mutants,
Fig 5. GRA7-III-induced activation of PLD1 was dependent on interaction with PLD1. (A) Bacterially purified 6xHis-GRA7-III and its mutants were
analyzed by Coomassie blue staining (left) or IB with αHis (right). (B) BMDMs from PKCα+/+ and PKCα-/- mice were stimulated with rGRA7-III (5 μg/ml) and
its mutants for the indicated times, followed by IB to detect phosphorylated and total forms of PLD1 and PLD2. Actin was used as a loading control. (C)
BMDMs were stimulated with rGRA7-III and its mutants for 30 min. and analyzed for PLD activity assay in vitro. Data shown are the means ± SD of five
experiments. (D) Fluorescence confocal images in BMDMs were stimulated with rGRA7 and its mutants for 30 min., fixed, immunostained with antibodies
for His (Alexa 488) and PLD1 (Alexa 568). Scale bar, 20 μm. The data are representative of three independent experiments with similar results (A, B, and
D).
doi:10.1371/journal.ppat.1006126.g005
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and then examined the induction of protein levels of Rab5, Rab7, LAMP1, and LAMP2 regula-
tors of phagosomal maturation in mycobacteria-containing phagosome fractions (phagosome
and phago-lysosome) subsequently purified by sucrose-step-gradient-ultra-centrifugations.
Interestingly, GRA7-induced MTB-containing phagosomes were recruited to late endosome
and lysosome marker Rab7, LAMP1, and LAMP2, indicating that GRA7 facilitates mycobacte-
rial phagosome-lysosome fusion in macrophages in a PKCα- and PLD1-dependent manner
(Fig 6A). Furthermore, GRA7 associated with PLD1 in phagosomal fractions in a binding-
dependent manner, and the phosphomimetic mutant (IS135D) of GRA7 markedly increased
Fig 6. GRA7-III-induced activation of PLD1 and phagosomal maturation were required for antimicrobial activity in MTB-infected
macrophages. (A and B) BMDMs were infected with MTB (MOI = 1) for 4 h and then stimulated with rGRA7 (5 μg/ml) and its mutants for 18
h. Mycobacteria-containing phagosome fractions were subsequently purified by sucrose-step-gradient-ultra-centrifugations, followed by IB
to detect αRab5, αRab7, αLAMP1, αLAMP2, αPLD1, αPKCα, and αActin (A) or IP with αPLD1 and IB with αHis, αPLD1, and αActin (B).
Quantitative analysis of the PLD1 interacts with His-rGRA7 in MTB-containing phagosomes band normalized to Actin is shown (lower).
(C and D) Intracellular survival of MTB was assessed by CFU assay. BMDMs were infected with MTB for 4 h, followed by treatment with
rGRA7, and then lysed to determine intracellular bacterial loads. (D, right) IB with αPLD1, αΑSC, and αActin in BMDMs. The data are
representative of five independent experiments with similar results (A and B). Data shown are the mean ±SD of five experiments (C and D).
Significant differences (*P < 0.05; **P < 0.01; ***P < 0.001) compared with PKCα+/+ and PKCα-/- (B) or rVector (C and D). CFU, colony-
forming units. ns, not significant.
doi:10.1371/journal.ppat.1006126.g006
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phagosomal trafficking and binding to PLD1, indicating that the constitutively active form
(IS135D) of GRA7 ‘rescued’ PKCα deficiency (Fig 6B). Consistently, the viability and growth
rate of intracellular MTB decreased following treatment with the phosphomimetic mutant
(IS135D) in BMDMs from PKCα+/+ and PKCα-/- mice, but not PLD1-/- mice in dose-dependent
manner (Fig 6C and 6D). These results collectively indicate that GRA7 facilitates phagosomal
maturation through interactions with PLD1 and thereby, exerts marked control of bacterial
killing activity against intracellular mycobacteria in a binding-dependent manner via PKCα.
GRA7-I and-III-dependent host protective effects against MTB infection
in vivo
Drawing on the observation that GRA7-I and -III associate with ASC and PLD1, respectively,
and which contributes to antimicrobial defense against MTB in macrophages (S7A Fig), we next
evaluated the in vivo efficacy of rGRA7 and its binding mutants in a mouse model of established
tuberculosis [31]. MTB-infected mice were given rGRA7 and its mutants, starting three weeks
after infection. Mice treated with rGRA7-WT alone, rGRA7-IWT+IIIWT, or rGRA7-IS53D+IIIS135D,
but not the binding deficient mutant (rGRA7-IS53A+IIIS135A) had significantly reduced bacillary
load in the lung, liver, and spleen, and reduced formation of lung granulomatous lesions in size
and number of foci, compared with vector-treated mice (Fig 7A and 7B). Notably, the phospho-
mimetic mutant (IS53D+IIIS135D) of rGRA7 drastically reduced bacillary load, at a level similar to
rGRA7-WT in PKCα+/+ and PKCα-/- mice.
We further investigated the effect of GRA7-III on in vivo host responses to MTB infection.
As shown in Fig 7C and 7D, treatment with PLD1-binding domain (IIIWT) and the phospho-
mimetic mutant (IIIS135D) of rGRA7 markedly increased bacterial killing effects and number
of granulomatous foci in PLD1+/+ mice, but not PLD1-/- mice. Treatment with the PLD1-bind-
ing deficient mutant (IIIS135A) of rGRA7 had no significant effect on bacterial killing or granu-
lomatous lesions in either PLD1+/+ or PLD1-/- mice, indicated that the anti-mycobacterial
effect of GRA7-III acts in a PLD1-binding dependent manner via PKCα in vivo. However, No
significant difference was observed for inflammation score in lung (S7B and S7C Fig). The
pharmacokinetics of therapeutic rGRA7 proteins were localized in alveolar macrophages was
maintained for up to 7 days and gradually cleared until 25 days was studied by the fluorescence
of the fluorophore Alexa 488-conjugated with the proteins (S8 Fig). These results unambigu-
ously show that host defenses against MTB infection are substantially affected by GRA7-I and
GRA7-III.
Discussion
The central finding of this study is that the PKCα-mediated phosphorylation of T. gondii
GRA7 is essential for the interaction between GRA7 and ASC or PLD1, which contributes to
antimicrobial defense against MTB (S9 Fig). Specifically, we found that (1) PKCα specific
phosphorylation of Ser52 and Ser135 of GRA7 in vitro and in vivo was functionally required
for ASC and PLD1 interactions with GRA7, respectively, (2) GRA7 was a novel substrate of
PKCα, (3) the N-terminal of GRA7 (GRA7-I) was sufficient for interaction with the PYD
domain of ASC in mitochondria, leading to ASC oligomerization and inflammasome activa-
tion, and subsequent antimicrobial activity, (4) GRA7-III interacted with the PX domain of
PLD1 in cytosol, facilitating its enzyme activity, phago-lysosomal biogenesis, and subsequent
antimicrobial activity, (5) GRA7-I and -III-dependent host protective effects against MTB
infection were demonstrated in vivo, and (6) a phosphomimetic mutant that constitutively
activated GRA7 ‘rescued’ PKCα deficiency both in vitro and in vivo. Collectively, these obser-
vations indicate that T. gondii GRA7-mediated HDTs leading to an antimicrobial response, as
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a novel host defense mechanism may provide a unique opportunity for urgently needed thera-
peutic intervention strategies for TB and other infectious diseases.
Although it is well established that dense granule protein GRA7 is important for immuno-
diagnosis of toxoplasmosis in patients [32,33], new candidates for further effective vaccine
development against T. gondii infection is the need [17,34,35]. Recent reports showed that
GRA7 is associated with T. gondii ROP5 was required for efficient phosphorylation of Irga6
and additional component of the ROP5/ROP18 kinase complex [22,36] and binding of ROP2
and ROP4 was shown [37] in T. gondii. However, the modulation of host innate immunity by
GRA7 in the early phases of infection is critical for the establishment of both the initial inva-
sion and the subsequent maintenance of latent infection is have not been fully elucidated.
Growing evidence suggests that host-pathogen interactions have led to the coevolution of
Fig 7. GRA7-I and -III showed anti-mycobacterial activity against MTB challenge in vivo. Schematic of the TB model treated with rGRA7
or vehicle (A, upper). (A) Bacterial loads in lung, liver, and spleen in PKCα+/+ and PKCα-/- mice. n = 10. (B) Histopathology scores were
obtained from H&E stained lung sections (left), as described in Methods. Number of granulomas observed in 10 different lung sections per
mouse (right). Scale bar, 500 μm. (C) Bacterial loads in lung, liver, and spleen in PLD1+/+ and PLD1-/- mice. n = 10. (D) Number of granulomas
observed in 10 different lung sections per mouse. Black bars represent the median values. Student’s t-test and Grubbs’ outlier test were used
for statistical analysis. The data are representative of two independent experiments with similar results. Significant differences (*P < 0.05;
**P < 0.01; ***P < 0.001) compared with PKCα+/+ and PLD1+/+.
doi:10.1371/journal.ppat.1006126.g007
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toxoplasmosis-causing T. gondii with its host [17,22,38]. GRA7 binds to poly(rC) binding pro-
tein 1/PCBP1 along with PCBP2 and hnRNPK, corresponding to the principal cellular poly
(rC) binding proteins according to yeast two-hybrid analysis. PCBP1 plays a part in the forma-
tion of a sequence-specific α-globin mRNP complex that is associated with the stability of α-
globin mRNA [38]. Additionally, GRA7 directly binds to the active dimer of Irga6 in a GTP-
dependent manner. The binding of GRA7 to Irga6 led to enhanced polymerization, rapid turn-
over, and eventual disassembly, which contributed to acute virulence in the mouse [22]. We
recently showed that the GRA7-V (aa 201–236) domain led to physical and functional associa-
tions with TRAF6. Furthermore, GRA7-V-induced Th1 immune responses and protective effi-
cacy were crucial for T. gondii infection in vivo [17]. In this study, we showed that host cell
ASC, PLD1, and PKCα bind to GRA7. The GRA7 protein interacted with a number of host
cell proteins including enzymes, and a broad spectrum of structural and functional subcellular
organellar proteins revealing a new facet of the role of GRA7 in the regulation of innate host
immune responses.
Our results correlate with those of previous studies showing that T. gondii is a novel activa-
tor of NLRP1 and NLRP3 inflammasomes by activating caspase-1, an enzyme that mediates
cleavage and release of the proinflammatory cytokines IL-1β and IL-18 in vitro and in vivo,
thereby establishing a role for these sensors in host resistance to toxoplasmosis [39–41]. Fur-
thermore, Millholland et al. showed that a Gα subunit (Gα)q-coupled host-signaling cascade is
required for the egress of T. gondii. Gαq-coupled signaling results in PKC-mediated loss of the
host cytoskeletal protein adducin and weakening of the cellular cytoskeleton. This cytoskeletal
compromise induces catastrophic Ca2+ influx mediated by the mechanosensitive cation chan-
nel TRPC6, which activates host calpain that in turn proteolyzes the host cytoskeleton allowing
parasite release [42]. T. gondii induces prostaglandin E2 biosynthesis in macrophages by regu-
lating arachidonic acid production through a Ca2+-dependent pathway and induction of cyclo-
oxygenase-2 expression by a PKC-dependent pathway [43,44]. Reinforcing the feasibility of
targeting host proteins as an antiparasitic strategy, mammalian PKC inhibitors demonstrate
activity in murine models of toxoplasmosis. In this study, we focused on the role of GRA7-I
and -III-dependent innate immunity. Future studies will aim to clarify the precise molecular
mechanisms of GRA7 and GRA7-II and -IV-related signaling pathways in inflammatory
responses and host defense.
HDTs aim to modulate immune responses in the TB lung [45,46]. Neutralization of pro-
inflammatory cytokines such as IL-6, TNF-α, VEGF, and IFN-α/β, as well as anti-inflamma-
tory IL-4, during severe pulmonary disease may help reduce ongoing parenchymal damage in
the MTB-infected lung [27,45–47]. Alternatively, suboptimal activation of anti-TB immune
responses due to regulatory T cell activity can be reversed by the use of the anti-cancer drug
cyclophosphamide. Drugs with anti-TB potential, such as metformin, imatinib, ibuprofen,
zileuton, valproic acid, and vorinostat as well as nutraceuticals such as 1,25D, may not only
abate the bacterial burden via host-dependent mechanisms, but also fine-tune the immune
response to MTB. These drugs increase phagocytosis of extracellular bacteria, improve emer-
gency myeloid response, and increase autophagic and apoptotic killing of bacteria, subse-
quently editing the T cell response in favor of the host. Immune checkpoint inhibition with
blockade of the PD-1/PD-1 ligand 1, CTLA-4/cytotoxic T lymphocyte-associated antigen 4,
LAG3/lymphocyte-activation gene 3, and TIM3/T cell immunoglobulin pathways may
improve the quality of the cellular immune response to MTB epitopes, as seen in cancer immu-
notherapy [4,5,45–47]. Our results partially correlate with those of previous studies showing
that host-directed immunotherapy with clinically approved drugs that augment prostaglandin
E2 level prevents acute mortality of MTB-infected mice. Thus, IL-1 and type I IFNs represent
two major counter-regulatory classes of inflammatory cytokines that control the outcome of
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MTB infection and are functionally linked via eicosanoids [27], and IL-1β either directly or via
enhancement by 1,25D promotes antimicrobial immunity against MTB infection [10,11]. Greco
et al. showed that PKC-mediated Ca2+ mobilization, PLD activity, and (auto)phagolysosome mat-
uration represent effector processes induced by apoptotic body-like liposomes carrying PA that
concur with the intracellular killing of MTB [14]. The MTB-containing phagosomes is involved
in arresting phagosome maturation and inhibiting phagolysosome biogenesis [6,8,9], however,
rGRA7-induced PKCα regulates phagocytosis, PLD-dependent the biogenesis of phagolysosomes
(Rab5 conversion to Rab7) by promoting the interaction of phagosomes with late endosomes
and lysosomes, and Rab7 regulated phagosomal acidification, which is important for the killing
of MTB in human macrophages [7,16]. Our current observations based on the study of GRA7-III
co-localized with PLD1 and PKCα in the cytoplasm (Fig 5D and S6 Fig) have the proposal the
localized on phagolysosomes, appearing as speckles and punctate spots, because of an artifact of
rGRA7 overexpression. Further studies are needed to localization organelle population.
The rGRA7 have a function of biologicals as potential therapeutics. However, these rGRA7
do not fulfil the requirements of direct anti-mycobacterial agent, which represent feasible alter-
natives to conventional chemotherapy to TB, due to the still unclear specificity and selectivity
does not enable linking the effects of rGRA7s to host immune systems, as well as limitation of
animal experimental model, unknown off-target effects, pharmacokinetics, safety data, and
their potential feasibility for in vivo proof-of-concept studies. Further analyses are required to
find out whether rGRA7s can be translated to the in vivo situation or be observed in the pres-
ence of physiological condition to patient with TB.
In conclusion, we provide evidence of a critical role of PKCα-mediated phosphorylation of
T. gondii GRA7 in the interaction between GRA7 and ASC or PLD1, which contributes to anti-
microbial defense against MTB (S9 Fig). GRA7-I and -III-dependent host protective effects
worked against MTB infection in vivo, and a phosphomimetic mutant that constitutively acti-
vated GRA7 ‘rescued’ PKCα deficiency. These observations reveal a new role for GRA7 in reg-
ulating innate immune responses in host protective immunity. Our findings establish proof of
concept for HDT strategies that manipulate host GRA7-mediated immune networks. Further
studies are needed to develop more effective GRA7-based potential therapeutic targets and to
understand how GRA7 regulates host defense strategies against TB and other infectious
diseases.
Supporting Information
S1 Fig. Identified of peptides by mass spectrometry analysis related to Fig 1A.
(TIF)
S2 Fig. GRA7 interaction with ASC and PLD1, but not PLD2, NLRP3, and NLRC4. (A)
THP-1 cells were stimulated with rGRA7 (5 μg/ml) for 30 min., followed by IP with αPLD1,
αTRAF6, or αASC and IB with αPLD1, αTRAF6, αASC, αHis, and αActin. (B) THP-1 cells
were stimulated with rGRA7 for the indicated times, followed by IP with αHis-agarose bead
and IB with αPLD2, αNLRP3, αNLRC4, αHis, and αActin. (C) THP-1 cells were pre-incu-
bated with Cytochalasin D (Cyto D, 10 μM), phagocytosis inhibitor or solvent control for 30
min before treated with Alexa488-conjugated rGRA7 for the indicated times, followed by flow
cytometry analysis to detect internalized Alexa488-rGRA7. The mean fluorescence intensity
values of Alexa488-rGRA7 from flow cytometry were used to generate phagocytosis rate kinet-
ics (bottom). (D) THP-1 cells were pre-incubated with Cytochalasin D (Cyto D, 5, 10, 20 μM)
and stimulated with rGRA7 for the indicated times, followed by IP with αHis-agarose bead
and IB with αPLD1, αTRAF6, αASC, αHis, and αActin. (E) Schematic diagram of the struc-
tures of PLD1 and its mutants. The data are representative of three independent experiments
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with similar results (A—D). SC, solvent control (0.1% DMSO).
(TIF)
S3 Fig. GRA7 interaction with ASC and PLD1 was dependent on PKCα. (A) Phos-tag and
SDS-PAGE analysis of GST-GRA7 expressed together with Flag-tagged PKCβ, PKCδ, or PKCξ
in 293T cells left untreated (CIP-) or treated calf intestinal alkaline phosphatase (CIP+), and
subjected to GST pulldown, followed by IB with αGST. WCLs were used for IB with αFlag or
αActin. (B) At 48 hr post-transfection with mammalian GST, GST-GRA7, or GST-GRA7-V
constructs together with V5-ASC or AU1-PLD1, 293T cells were used for GST pulldown, fol-
lowed by IB with αV5 and αAU1. WCLs were used for IB with αGST, αV5, αAU1, αPKCα or
αActin. (C) At 48 hr transduction with lentivirus-shRNA-NS or lentivirus-shRNA-PKCα
(MOI = 50), THP-1 cells were stimulated with rGRA7 (5 μg/ml) for 30 min., followed by IP
with αHis-agarose bead and IB with αASC, αPLD1, αPKCα, and αActin. (D) THP-1 cells were
pre-incubated with PKCα (C2-4) (5, 10, 20 μM) and stimulated with rGRA7 for 30 min., fol-
lowed by IP with αHis-agarose bead and IB with αPLD1, αASC, αPKCα, and αActin. The data
are representative of three independent experiments with similar results (A—D).
(TIF)
S4 Fig. GRA7-I activate inflammasomes in mitochondria in ASC-binding dependent man-
ner. (A) BMDMs from PKCα+/+ and PKCα-/- were stimulated with rGRA7 (5 μg/ml) and its
mutants for the indicated times and culture supernatants were harvested and analyzed for
cytokine ELISA for TNF-α and IL-6. (B) BMDMs was transduced with lentivirus-shRNA-NS or
lentivirus-shRNA-ASC (MOI = 100) with polybrene (8 μg/mL) (right) for 2 days, followed by
IB with αASC, αPLD1, and αActin. (C) The number of ASC pyroptosome was counted using a
fluorescent microscope and the ASC speck-containing cells were represented as a relative per-
centage compared to the total cell number related to Fig 3E. (D) BMDMs from PKCα+/+ and
PKCα-/- were stimulated with rGRA7-I and its mutants for 18 h. The cells were then subcellu-
larly fractionated, subjected to co-IP with αHis, followed by IB analysis with αASC and αPKCα.
Levels of tubulin (cytosolic), calnexin (endoplasmic reticulum (ER) and mitochondria-associ-
ated membrane (MAM)), fatty acid CoA ligase 4 (FACL4, MAM) and voltage-dependent anion
channels (VDAC, mitochondrial) protein in each fraction were determined by IB analysis. Data
shown are the means ± SD of five experiments (A and C). The data are representative of three
independent experiments with similar results (B and D).
(TIF)
S5 Fig. rGRA7-I’s effect on mycobacteria growth. M. tuberculosis H37Rv were cultures in
7H9 broth contained 10% OADC in presence of rVector, rGRA7-WT, -I, or -III (10 μg/ml) for
the indicated times at 37˚C. Measure the OD600 every 3 days. Data shown are the means ± SD
of three experiments.
(TIF)
S6 Fig. GRA7-III interacts with PLD1 in cytosol. (A) The co-localization index (%) between
PLD1 and GRA7 were quantified and validated statistically by Pearson coefficient, as specified by
the ZEN 2009 software, related to Fig 5D. Data shown are the means ± SD of five experiments.
(B) BMDMs from PKCα+/+ and PKCα-/- were stimulated with rGRA7-III and its mutants for 18
h. The cells were then subcellularly fractionated, subjected to co-IP with αHis, followed by IB
analysis with αPLD1 and αPKCα. Levels of tubulin (cytosolic), calnexin (endoplasmic reticulum
(ER) and mitochondria-associated membrane (MAM)), fatty acid CoA ligase 4 (FACL4, MAM)
and voltage-dependent anion channels (VDAC, mitochondrial) protein in each fraction were
determined by IB analysis. The data are representative of three independent experiments with
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similar results.
(TIF)
S7 Fig. Effects of GRA7-induced anti-mycobacterial activity and inflammation score in
vivo. (A) Intracellular survival of MTB was assessed by CFU assay. BMDMs were infected
with MTB for 4 h, followed by treatment with rGRA7, and then lysed to determine intracellu-
lar bacterial loads. Data shown are the mean ± SD of five experiments. Significant differences
(P< 0.01; P< 0.001) compared with rVector. (B and C) Whole lung photo (B, left,
related to Fig 7B) and immunopathology scores were obtained from H&E stained lung sec-
tions (B, right and C), as described in Methods. The data are representative of three indepen-
dent experiments with similar results (B, left, 12.5 X). n = 10 (B, right and C). CFU, colony-
forming units. ns, not significant.
(TIF)
S8 Fig. Therapeutic rGRA7 proteins are uptaken by cells of the reticuloendothelial system
in the lung. Schematic of the pharmacokinetic analysis in TB model treated with rGRA7
(upper). Mycobacteria-infected mice were injected with Alexa488-conjugated proteins for 7
consecutive days and then lung was harvested at indicated time points and immune-stained
with αMac-3 or DAPI. Pharmacokinetic analysis of proteins in the lung was visualized through
a multi-photon confocal laser scanning microscope system. The data are representative of
three independent experiments with similar results. Scale bar, 10 μm.
(TIF)
S9 Fig. Schematic model for the roles of GRA7 and GRA7-mediated regulatory pathways
against intracellular pathogens such as Mycobacteria and T. gondii. Please see the Discus-
sion for detail.
(TIF)
S1 Text.
(DOC)
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